JPH08253417A - 脳又はｃｎｓのエストロゲン陽性腫瘍抑制用製剤 - Google Patents

脳又はｃｎｓのエストロゲン陽性腫瘍抑制用製剤

Info

Publication number
JPH08253417A
JPH08253417A JP8039488A JP3948896A JPH08253417A JP H08253417 A JPH08253417 A JP H08253417A JP 8039488 A JP8039488 A JP 8039488A JP 3948896 A JP3948896 A JP 3948896A JP H08253417 A JPH08253417 A JP H08253417A
Authority
JP
Japan
Prior art keywords
estrogen
brain
compound
cns
raloxifene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP8039488A
Other languages
English (en)
Japanese (ja)
Inventor
Robin Sharon Lee Fuchs-Young
ロビン・シャロン・リー・フックス−ヤング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JPH08253417A publication Critical patent/JPH08253417A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP8039488A 1995-02-28 1996-02-27 脳又はｃｎｓのエストロゲン陽性腫瘍抑制用製剤 Withdrawn JPH08253417A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39638995A 1995-02-28 1995-02-28
US396389 1995-02-28

Publications (1)

Publication Number Publication Date
JPH08253417A true JPH08253417A (ja) 1996-10-01

Family

ID=23567005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8039488A Withdrawn JPH08253417A (ja) 1995-02-28 1996-02-27 脳又はｃｎｓのエストロゲン陽性腫瘍抑制用製剤

Country Status (3)

Country Link
EP (1) EP0729754A2 (enExample)
JP (1) JPH08253417A (enExample)
CA (1) CA2170480A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990129A (en) * 1997-09-23 1999-11-23 Eli Lilly And Company Methods for regulating trkA expression
EP1113007A1 (en) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
FR2873692B1 (fr) * 2004-07-29 2006-12-01 Univ Claude Bernard Lyon COMPOSITIONS CONTENANT, EN ASSOCIATION AVEC UN AGENT ANTIMICROBIEN, UN COMPOSE THIOPHENIQUE OU BENZOTHIOPHENIQUE DE FORMULE(I)PRESENTANT UNE ACTIVITE INHIBITRICE DE POMPE NorA
WO2008025509A1 (en) * 2006-09-01 2008-03-06 Bayer Schering Pharma Aktiengesellschaft Benzofuran and benzothiophene derivatives useful in the treatment of cancers of the central nervous system

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58836B1 (en) * 1984-08-02 1993-11-17 Labrie Fernand Pharmaceutical composition for combination therapy of hormone dependent cancers
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
IL115582A0 (en) * 1994-10-14 1996-01-19 Lilly Co Eli Methods for treating resistant tumors

Also Published As

Publication number Publication date
CA2170480A1 (en) 1996-08-29
EP0729754A3 (enExample) 1996-09-11
EP0729754A2 (en) 1996-09-04

Similar Documents

Publication Publication Date Title
CA2101356C (en) Improvements in or relating to benzothiophenes
AU691844B2 (en) Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
US5691355A (en) Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
RU2138261C1 (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования расстройств цнс у женщин в постменопаузе
AU701701B2 (en) Methods of inhibiting breast disorders
US5843962A (en) Methods of inhibiting ovarian dysgenesis, delayed puberty, or sexual infantilism
US5451590A (en) Methods of inhibiting sexual precocity
CA2138494A1 (en) Methods of inhibiting turner's syndrome
US5843974A (en) Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
MXPA97009466A (en) Medicine to inhibit the melan
JPH08253417A (ja) 脳又はｃｎｓのエストロゲン陽性腫瘍抑制用製剤
AU701267B2 (en) Methods of inhibiting growth hormone effects
AU707892B2 (en) Methods of inhibiting colon tumors
WO1997026878A1 (en) Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
MXPA97005215A (en) Use of 2-phenyl-3-aroylbenzotiophenes to inhibit effects of growth hormone

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20030506